<html><head><meta content="text/html; charset=ISO-8859-1"http-equiv="Content-Type"><head><link rel="stylesheet" type="text/css" href="../malletgui.css" /><title>Doc75.html</title></head><table style=" text-align: left;" border="0" cellpadding="2" cellspacing="2"><tbody><body><h4><u>DOC</u> :2014-11-10.txt</h4><br><textarea style="width: 50%; height: 150px;">Patient non-adherence: Perceived challenge or next big opportunityPatient non-adherence: Perceived challenge or next big opportunity
Sanjeev Jha        Last Updated: November 17, 2014  | 16:44 IST
Sanjeev Jha
As regulatory hurdles increase and product pipelines shrink, pharmaceutical companies must identify new revenue drivers to maintain growth. Addressing patient non-adherence and thereby improving health outcomes, seems like a popular answer to the problem, yet improving patient adherence is an incommodious task.
As per a 2013 study by 'Cutting Edge Information', pharma companies in the US alone are trying to fight non-adherence costs of more than $290 billion, as almost 50 per cent of patients in the US don't take their medications as prescribed. Considering the socio-economic condition of patients in India, we can safely assume the non-adherence percentage to be higher in the emerging economies.
Let's take an example of patients with Type-2 Diabetes, who do not produce enough insulin to convert blood sugar (glucose) into energy, causing glucose levels to build up in their body. Effective management of Type-2 Diabetes, which includes up to 90 per cent of all diabetes cases, usually involves a multi-pronged approach that includes drug therapies and lifestyle changes. The challenge for primary care physicians (PCPs) is getting patients to adhere to the plan. A recent study in The New ...</textarea><br><br>Top topics in this doc (% words in doc assigned to this topic) <br><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td><td>(18%)</td><td><a href=../Topics/Topic5.html>year financial people day government minister times modi cent women</a> ...</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td><td>(17%)</td><td><a href=../Topics/Topic1.html>year cent market rs bank month sales high growth years</a> ...</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td><td>(16%)</td><td><a href=../Topics/Topic9.html>november people times financial minister state government police friday chief</a> ...</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td><td>(13%)</td><td><a href=../Topics/Topic8.html>india modi bjp indian minister billion president party china state</a> ...</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td><td>(13%)</td><td><a href=../Topics/Topic4.html>october government financial times bjp year rs cent party state</a> ...</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td><td>(13%)</td><td><a href=../Topics/Topic10.html>financial times india company percent share rs ft coal shares</a> ...</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td><td>(7%)</td><td><a href=../Topics/Topic2.html>rs company cent india october growth market year ist global</a> ...</td></tr></tbody></table><br><br><br><br><a href=../all_topics.html><b>[Index]</b></a></body></html>